LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

Home・Akcijų sąrašas・Design Therapeutics Inc

Design Therapeutics Inc

Uždarymo kaina

10.16 5.94

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

10.16

Max

10.16

Pagrindiniai rodikliai
By Trading Economics
Pajamos	2.1M -17M
Darbuotojai	55
EBITDA	4.7M -17M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+52.43% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-03-09

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	201M 574M
Ankstesnė atidarymo kaina	4.22
Ankstesnė uždarymo kaina	10.16

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

3.26 / 3.63 Palaikymas ir pasipriešinimas

Design Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-20 17:37; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Regulatory Waiting Period for Warner Bid Expires -- Update

2026-02-20 16:18; UTC

Pagrindinės rinkos jėgos

Footwear Stocks Rise After Supreme Court Strikes Down Tariffs

2026-02-20 23:12; UTC

Įsigijimai, susijungimai, perėmimai

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

2026-02-20 22:12; UTC

Uždarbis

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

2026-02-20 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-20 21:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-02-20 21:23; UTC

Uždarbis

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

2026-02-20 21:20; UTC

Rinkos pokalbiai

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

2026-02-20 21:01; UTC

Įsigijimai, susijungimai, perėmimai

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

2026-02-20 20:38; UTC

Rinkos pokalbiai

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

2026-02-20 20:17; UTC

Rinkos pokalbiai

Oil Futures Mixed As Market Awaits U.S.-Iran Moves -- Market Talk

2026-02-20 20:11; UTC

Rinkos pokalbiai

Traders Await Word on USMCA Exemption For Trump's Global 10% Tariff -- Market Talk

2026-02-20 19:59; UTC

Rinkos pokalbiai

U.S. Tariff Ruling Could Make Things Worse for Mexico -- Market Talk

2026-02-20 19:58; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Netflix Seen as Not Needing Warner Bros. Deal -- Market Talk

2026-02-20 19:49; UTC

Rinkos pokalbiai

Mexico's Revised 4Q GDP Expected to Confirm Pick-Up -- Market Talk

2026-02-20 19:09; UTC

Rinkos pokalbiai

Precious Metals Settle Higher After Tariff Ruling -- Market Talk

2026-02-20 19:00; UTC

Rinkos pokalbiai

U.S. Oil, Gas Rig Counts Unchanged on Week -- Market Talk

2026-02-20 18:28; UTC

Rinkos pokalbiai

Ontario Premier Warns Fight Against U.S. Tariffs Isn't Over -- Market Talk

2026-02-20 18:20; UTC

Rinkos pokalbiai

Tariff Ruling Seen Positive for Some Retailers, Mixed for Others -- Market Talk

2026-02-20 18:05; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2026-02-20 18:04; UTC

Rinkos pokalbiai

Trade Uncertainty in Canada to Remain Until USMCA Resolved -- Market Talk

2026-02-20 17:38; UTC

Rinkos pokalbiai

Canada's Small Firms Look Toward Increased U.S. Tariff Opposition -- Market Talk

2026-02-20 17:24; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-02-20 17:24; UTC

Rinkos pokalbiai

Correction to Treasury Yields Fall Market Talk

2026-02-20 17:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-02-20 16:53; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2026-02-20 16:53; UTC

Rinkos pokalbiai

Canada Dollar Steady, Market Focus on USMCA Review -- Market Talk

2026-02-20 16:45; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-02-20 16:45; UTC

Rinkos pokalbiai

U.K. Public Finances Supportive of Gilts in Near-Term -- Market Talk

2026-02-20 16:40; UTC

Rinkos pokalbiai

Trade Threats Facing Canada Not Removed by Supreme Court's Ruling -- Market Talk

Akcijų palyginimas

Kainos pokytis

Design Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

52.43% į viršų

12 mėnesių prognozė

Vidutinis 15.67 USD 52.43%

Aukščiausias 18 USD

Žemiausias 14 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Design Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

3 ratings

Pirkti

Laikyti

Parduoti

Remiantis 3 analitikų, pateikusių Design Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

3.26 / 3.63Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.